169 related articles for article (PubMed ID: 29858753)
1. Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer.
Reddy JP; Atkinson RL; Larson R; Burks JK; Smith D; Debeb BG; Ruffell B; Creighton CJ; Bambhroliya A; Reuben JM; Van Laere SJ; Krishnamurthy S; Symmans WF; Brewster AM; Woodward WA
Breast Cancer Res Treat; 2018 Sep; 171(2):283-293. PubMed ID: 29858753
[TBL] [Abstract][Full Text] [Related]
2. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
3. IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages.
Mohamed HT; El-Husseiny N; El-Ghonaimy EA; Ibrahim SA; Bazzi ZA; Cavallo-Medved D; Boffa MB; El-Shinawi M; Mohamed MM
Curr Probl Cancer; 2018; 42(2):215-230. PubMed ID: 29459177
[TBL] [Abstract][Full Text] [Related]
4. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency.
Atkinson RL; Yang WT; Rosen DG; Landis MD; Wong H; Lewis MT; Creighton CJ; Sexton KR; Hilsenbeck SG; Sahin AA; Brewster AM; Woodward WA; Chang JC
Breast Cancer Res; 2013; 15(5):R77. PubMed ID: 24008095
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory Breast Cancer Promotes Development of M2 Tumor-Associated Macrophages and Cancer Mesenchymal Cells through a Complex Chemokine Network.
Valeta-Magara A; Gadi A; Volta V; Walters B; Arju R; Giashuddin S; Zhong H; Schneider RJ
Cancer Res; 2019 Jul; 79(13):3360-3371. PubMed ID: 31043378
[TBL] [Abstract][Full Text] [Related]
6. Macrophages Enhance Migration in Inflammatory Breast Cancer Cells via RhoC GTPase Signaling.
Allen SG; Chen YC; Madden JM; Fournier CL; Altemus MA; Hiziroglu AB; Cheng YH; Wu ZF; Bao L; Yates JA; Yoon E; Merajver SD
Sci Rep; 2016 Dec; 6():39190. PubMed ID: 27991524
[TBL] [Abstract][Full Text] [Related]
7. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
[TBL] [Abstract][Full Text] [Related]
8. Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer.
Remo A; Simeone I; Pancione M; Parcesepe P; Finetti P; Cerulo L; Bensmail H; Birnbaum D; Van Laere SJ; Colantuoni V; Bonetti F; Bertucci F; Manfrin E; Ceccarelli M
J Transl Med; 2015 May; 13():138. PubMed ID: 25928084
[TBL] [Abstract][Full Text] [Related]
9. MARCKS protein overexpression in inflammatory breast cancer.
Manai M; Thomassin-Piana J; Gamoudi A; Finetti P; Lopez M; Eghozzi R; Ayadi S; Lamine OB; Manai M; Rahal K; Charafe-Jauffret E; Jacquemier J; Viens P; Birnbaum D; Boussen H; Chaffanet M; Bertucci F
Oncotarget; 2017 Jan; 8(4):6246-6257. PubMed ID: 28009981
[TBL] [Abstract][Full Text] [Related]
10. Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype.
Funakoshi Y; Wang Y; Semba T; Masuda H; Hout D; Ueno NT; Wang X
PLoS One; 2019; 14(9):e0222336. PubMed ID: 31532791
[TBL] [Abstract][Full Text] [Related]
11. Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC).
Joglekar-Javadekar M; Van Laere S; Bourne M; Moalwi M; Finetti P; Vermeulen PB; Birnbaum D; Dirix LY; Ueno N; Carter M; Rains J; Ramachandran A; Bertucci F; van Golen KL
Neoplasia; 2017 Jul; 19(7):564-573. PubMed ID: 28609680
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model.
Lacerda L; Debeb BG; Smith D; Larson R; Solley T; Xu W; Krishnamurthy S; Gong Y; Levy LB; Buchholz T; Ueno NT; Klopp A; Woodward WA
Breast Cancer Res; 2015 Mar; 17(1):42. PubMed ID: 25887413
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models.
Wolfe AR; Trenton NJ; Debeb BG; Larson R; Ruffell B; Chu K; Hittelman W; Diehl M; Reuben JM; Ueno NT; Woodward WA
Oncotarget; 2016 Dec; 7(50):82482-82492. PubMed ID: 27756885
[TBL] [Abstract][Full Text] [Related]
14. High endogenous CCL2 expression promotes the aggressive phenotype of human inflammatory breast cancer.
Rogic A; Pant I; Grumolato L; Fernandez-Rodriguez R; Edwards A; Das S; Sun A; Yao S; Qiao R; Jaffer S; Sachidanandam R; Akturk G; Karlic R; Skobe M; Aaronson SA
Nat Commun; 2021 Nov; 12(1):6889. PubMed ID: 34824220
[TBL] [Abstract][Full Text] [Related]
15. Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties.
Mohamed MM; El-Ghonaimy EA; Nouh MA; Schneider RJ; Sloane BF; El-Shinawi M
Int J Biochem Cell Biol; 2014 Jan; 46():138-47. PubMed ID: 24291763
[TBL] [Abstract][Full Text] [Related]
16. Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer.
Provance OK; Lewis-Wambi J
Breast Cancer Res; 2019 May; 21(1):59. PubMed ID: 31060575
[TBL] [Abstract][Full Text] [Related]
17. Role of adipose tissue-derived cytokines in the progression of inflammatory breast cancer in patients with obesity.
Ibrahim AS; El-Shinawi M; Sabet S; Ibrahim SA; Mohamed MM
Lipids Health Dis; 2022 Aug; 21(1):67. PubMed ID: 35927653
[TBL] [Abstract][Full Text] [Related]
18. Gene set analysis of post-lactational mammary gland involution gene signatures in inflammatory and triple-negative breast cancer.
Bambhroliya A; Van Wyhe RD; Kumar S; Debeb BG; Reddy JP; Van Laere S; El-Zein R; Rao A; Woodward WA
PLoS One; 2018; 13(4):e0192689. PubMed ID: 29617367
[TBL] [Abstract][Full Text] [Related]
19. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
[TBL] [Abstract][Full Text] [Related]
20. Genomic and expression analysis of microdissected inflammatory breast cancer.
Woodward WA; Krishnamurthy S; Yamauchi H; El-Zein R; Ogura D; Kitadai E; Niwa S; Cristofanilli M; Vermeulen P; Dirix L; Viens P; van Laere S; Bertucci F; Reuben JM; Ueno NT
Breast Cancer Res Treat; 2013 Apr; 138(3):761-72. PubMed ID: 23568481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
